Jubilant Pharmova Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: March 3, 2026, 12:51 pm

Market Cap	13,546 Cr.
Current Price	850
Intrinsic Value	₹943.75
High / Low	1,250/802
Stock P/E	29.4
Book Value	414
Dividend Yield	0.59 %
ROCE	9.54 %
ROE	9.55 %
Face Value	1.00
PEG Ratio	32.95

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Jubilant Pharmova Ltd

Competitors

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
Jubilant Pharmova Ltd	13,546 Cr.	850	1,250/802	29.4	414	0.59 %	9.54 %	9.55 %	1.00
Alembic Pharmaceuticals Ltd	13,863 Cr.	705	1,108/671	20.9	271	1.56 %	13.0 %	11.4 %	2.00
Granules India Ltd	13,939 Cr.	574	627/412	25.6	164	0.26 %	15.1 %	13.9 %	1.00
Caplin Point Laboratories Ltd	12,716 Cr.	1,673	2,397/1,551	20.7	416	0.36 %	25.8 %	22.7 %	2.00
Concord Biotech Ltd	12,563 Cr.	1,201	2,150/1,057	39.6	174	0.89 %	28.4 %	21.4 %	1.00
Industry Average	20,512.19 Cr	1,093.42		53.22	201.81	0.38%	16.35%	15.16%	6.10

All Competitor Stocks of Jubilant Pharmova Ltd

Quarterly Result

Metric	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Sales	1,552	1,678	1,587	1,680	1,677	1,759	1,732	1,752	1,822	1,929	1,901	1,966	2,122
Expenses	1,408	1,459	1,419	1,438	1,459	1,487	1,480	1,463	1,535	1,584	1,611	1,625	1,833
Operating Profit	144	219	168	242	218	271	252	289	287	345	290	341	289
OPM %	9%	13%	11%	14%	13%	15%	15%	17%	16%	18%	15%	17%	14%
Other Income	10	21	9	19	49	-151	410	8	-10	9	12	4	-19
Interest	51	56	62	66	71	73	71	61	56	53	49	50	56
Depreciation	94	271	90	97	95	101	91	91	91	95	98	105	121
Profit before tax	9	-86	25	98	101	-54	500	144	130	206	154	190	93
Tax %	285%	16%	76%	37%	34%	15%	4%	29%	23%	27%	34%	37%	40%
Net Profit	-16	-100	6	62	66	-62	482	102	101	151	102	120	56
EPS in Rs	-0.98	-6.15	0.40	3.92	4.19	-3.68	30.26	6.45	6.33	9.64	6.46	7.55	3.51

Last Updated: March 4, 2026, 5:46 am

Below is a detailed analysis of the quarterly data for Jubilant Pharmova Ltd based on the most recent figures (Dec 2025) and their trends compared to the previous period:

For Sales, as of Dec 2025, the value is 2,122.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,966.00 Cr. (Sep 2025) to 2,122.00 Cr., marking an increase of 156.00 Cr..
For Expenses, as of Dec 2025, the value is 1,833.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,625.00 Cr. (Sep 2025) to 1,833.00 Cr., marking an increase of 208.00 Cr..
For Operating Profit, as of Dec 2025, the value is 289.00 Cr.. The value appears to be declining and may need further review. It has decreased from 341.00 Cr. (Sep 2025) to 289.00 Cr., marking a decrease of 52.00 Cr..
For OPM %, as of Dec 2025, the value is 14.00%. The value appears to be declining and may need further review. It has decreased from 17.00% (Sep 2025) to 14.00%, marking a decrease of 3.00%.
For Other Income, as of Dec 2025, the value is -19.00 Cr.. The value appears to be declining and may need further review. It has decreased from 4.00 Cr. (Sep 2025) to -19.00 Cr., marking a decrease of 23.00 Cr..
For Interest, as of Dec 2025, the value is 56.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 50.00 Cr. (Sep 2025) to 56.00 Cr., marking an increase of 6.00 Cr..
For Depreciation, as of Dec 2025, the value is 121.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 105.00 Cr. (Sep 2025) to 121.00 Cr., marking an increase of 16.00 Cr..
For Profit before tax, as of Dec 2025, the value is 93.00 Cr.. The value appears to be declining and may need further review. It has decreased from 190.00 Cr. (Sep 2025) to 93.00 Cr., marking a decrease of 97.00 Cr..
For Tax %, as of Dec 2025, the value is 40.00%. The value appears to be increasing, which may not be favorable. It has increased from 37.00% (Sep 2025) to 40.00%, marking an increase of 3.00%.
For Net Profit, as of Dec 2025, the value is 56.00 Cr.. The value appears to be declining and may need further review. It has decreased from 120.00 Cr. (Sep 2025) to 56.00 Cr., marking a decrease of 64.00 Cr..
For EPS in Rs, as of Dec 2025, the value is 3.51. The value appears to be declining and may need further review. It has decreased from 7.55 (Sep 2025) to 3.51, marking a decrease of 4.04.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 24, 2026, 5:09 pm

Metric	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	5,762	5,751	5,749	5,861	7,518	9,111	5,976	6,099	6,130	6,282	6,703	7,234	7,918
Expenses	4,763	5,141	4,493	4,510	5,995	7,367	4,428	4,695	4,980	5,503	5,802	6,061	6,653
Operating Profit	999	610	1,256	1,352	1,522	1,744	1,548	1,403	1,150	779	901	1,173	1,266
OPM %	17%	11%	22%	23%	20%	19%	26%	23%	19%	12%	13%	16%	16%
Other Income	-173	86	4	19	36	-249	225	263	8	-9	-76	416	5
Interest	337	368	371	341	284	220	200	184	145	188	272	240	208
Depreciation	281	288	347	291	415	371	340	349	382	554	382	369	419
Profit before tax	207	40	542	738	859	904	1,233	1,133	630	28	170	981	644
Tax %	34%	200%	29%	22%	26%	36%	27%	26%	34%	333%	57%	15%
Net Profit	138	-40	387	575	634	577	898	836	413	-65	73	836	430
EPS in Rs	6.84	-3.63	24.60	36.14	40.35	36.06	56.39	52.47	25.98	-3.83	4.84	52.69	27.16
Dividend Payout %	43%	-83%	12%	8%	7%	12%	9%	10%	19%	-130%	102%	9%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024	2024-2025
YoY Net Profit Growth (%)	-128.99%	1067.50%	48.58%	10.26%	-8.99%	55.63%	-6.90%	-50.60%	-115.74%	212.31%	1045.21%
Change in YoY Net Profit Growth (%)	0.00%	1196.49%	-1018.92%	-38.32%	-19.25%	64.62%	-62.54%	-43.69%	-65.14%	328.05%	832.90%

Jubilant Pharmova Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:	2%
5 Years:	4%
3 Years:	6%
TTM:	8%

Compounded Profit Growth
10 Years:	24%
5 Years:	-10%
3 Years:	10%
TTM:	107%

Stock Price CAGR
10 Years:	15%
5 Years:	8%
3 Years:	48%
1 Year:	14%

Return on Equity
10 Years:	10%
5 Years:	6%
3 Years:	1%
Last Year:	10%

Last Updated: September 5, 2025, 8:35 am

Balance Sheet

Last Updated: December 4, 2025, 1:30 am

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Sep 2025
Equity Capital	15	16	16	16	16	16	16	16	16	16	16	16	16
Reserves	2,611	2,438	2,951	3,420	4,071	4,793	5,588	4,726	5,303	5,383	5,418	6,239	6,576
Borrowings	4,395	4,793	4,493	4,045	3,469	4,840	4,808	2,830	3,192	3,677	3,664	2,731	2,883
Other Liabilities	1,842	1,372	1,280	1,417	1,902	1,670	1,898	1,192	1,319	1,853	2,240	3,598	4,047
Total Liabilities	8,864	8,619	8,740	8,899	9,457	11,319	12,310	8,763	9,830	10,929	11,338	12,584	13,521
Fixed Assets	5,099	4,911	5,104	5,107	5,401	5,648	6,340	4,609	4,871	5,183	5,091	5,176	7,354
CWIP	472	597	611	684	671	901	768	897	1,090	1,562	2,103	3,630	2,344
Investments	34	40	85	103	124	115	69	241	239	256	42	44	45
Other Assets	3,259	3,071	2,939	3,006	3,262	4,654	5,133	3,017	3,631	3,928	4,101	3,735	3,778
Total Assets	8,864	8,619	8,740	8,899	9,457	11,319	12,310	8,763	9,830	10,929	11,338	12,584	13,521

Below is a detailed analysis of the balance sheet data for Jubilant Pharmova Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

For Equity Capital, as of Sep 2025, the value is 16.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 16.00 Cr..
For Reserves, as of Sep 2025, the value is 6,576.00 Cr.. The value appears strong and on an upward trend. It has increased from 6,239.00 Cr. (Mar 2025) to 6,576.00 Cr., marking an increase of 337.00 Cr..
For Borrowings, as of Sep 2025, the value is 2,883.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 2,731.00 Cr. (Mar 2025) to 2,883.00 Cr., marking an increase of 152.00 Cr..
For Other Liabilities, as of Sep 2025, the value is 4,047.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3,598.00 Cr. (Mar 2025) to 4,047.00 Cr., marking an increase of 449.00 Cr..
For Total Liabilities, as of Sep 2025, the value is 13,521.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 12,584.00 Cr. (Mar 2025) to 13,521.00 Cr., marking an increase of 937.00 Cr..
For Fixed Assets, as of Sep 2025, the value is 7,354.00 Cr.. The value appears strong and on an upward trend. It has increased from 5,176.00 Cr. (Mar 2025) to 7,354.00 Cr., marking an increase of 2,178.00 Cr..
For CWIP, as of Sep 2025, the value is 2,344.00 Cr.. The value appears to be declining and may need further review. It has decreased from 3,630.00 Cr. (Mar 2025) to 2,344.00 Cr., marking a decrease of 1,286.00 Cr..
For Investments, as of Sep 2025, the value is 45.00 Cr.. The value appears strong and on an upward trend. It has increased from 44.00 Cr. (Mar 2025) to 45.00 Cr., marking an increase of 1.00 Cr..
For Other Assets, as of Sep 2025, the value is 3,778.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,735.00 Cr. (Mar 2025) to 3,778.00 Cr., marking an increase of 43.00 Cr..
For Total Assets, as of Sep 2025, the value is 13,521.00 Cr.. The value appears strong and on an upward trend. It has increased from 12,584.00 Cr. (Mar 2025) to 13,521.00 Cr., marking an increase of 937.00 Cr..

Notably, the Reserves (6,576.00 Cr.) exceed the Borrowings (2,883.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity +	772	783	1,099	1,268	1,303	1,122	1,543	1,784	838	661	971	1,072
Cash from Investing Activity +	-164	-362	-309	-465	-614	-1,018	-267	-727	-323	-474	-596	512
Cash from Financing Activity +	-414	-503	-843	-686	-901	657	-1,050	-1,709	-33	-157	-432	-1,453
Net Cash Flow	194	-82	-52	117	-212	761	225	-652	482	30	-58	132

Free Cash Flow

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Free Cash Flow	995.00	606.00	-3.00	-3.00	-2.00	-3.00	-3.00	-1.00	-2.00	776.00	898.00	-1.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Debtor Days	51	52	60	63	55	51	79	49	55	56	50	45
Inventory Days	200	169	207	223	177	147	463	268	308	268	220	178
Days Payable	107	99	106	137	145	106	273	124	139	160	146	158
Cash Conversion Cycle	144	122	162	149	87	92	268	194	224	165	124	65
Working Capital Days	-92	12	4	50	45	45	62	74	56	57	56	16
ROCE %	11%	6%	13%	15%	15%	16%	15%	12%	10%	3%	7%	10%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Promoters	50.67%	50.67%	50.67%	50.67%	50.67%	50.67%	50.67%	50.67%	50.67%	47.67%	47.67%	47.67%
FIIs	23.22%	23.20%	23.20%	20.29%	19.06%	19.50%	17.94%	16.96%	17.23%	17.40%	16.56%	15.96%
DIIs	1.62%	1.63%	1.64%	2.89%	3.77%	4.06%	5.66%	6.99%	7.05%	9.52%	10.53%	11.23%
Government	1.24%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Public	23.11%	23.91%	23.89%	25.56%	25.91%	25.18%	25.17%	24.82%	24.48%	24.83%	24.60%	24.57%
Others	0.13%	0.59%	0.59%	0.58%	0.58%	0.58%	0.56%	0.56%	0.56%	0.56%	0.63%	0.57%
No. of Shareholders	97,935	93,375	89,376	86,588	92,264	81,992	89,456	1,02,442	96,526	99,673	93,336	90,133

Shareholding Pattern Chart

No. of Shareholders

Jubilant Pharmova Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund Name	No of Shares	AUM (%)	Amount Invested (Cr)	Previous Number of Shares	Previous Date	Percentage Change
Quant Small Cap Fund	2,947,185	1.06	289.38	N/A	N/A	N/A
Bandhan Small Cap Fund	2,084,564	1.06	204.68	1,967,867	2026-02-23 03:11:26	5.93%
Kotak Multicap Fund	1,873,926	0.81	184	1,842,613	2026-01-24 23:50:51	1.7%
Bandhan Focused Fund	982,101	4.84	96.43	955,222	2026-02-23 08:23:41	2.81%
Kotak Special Opportunities Fund	650,000	4.48	63.82	N/A	N/A	N/A
Kotak Contra Fund	578,400	1.12	56.79	N/A	N/A	N/A
Aditya Birla Sun Life Small Cap Fund	500,687	1.03	49.16	499,254	2026-02-21 00:51:05	0.29%
HDFC Manufacturing Fund	500,000	0.47	49.1	N/A	N/A	N/A
KotaK MNC Fund	360,000	1.8	35.35	N/A	N/A	N/A
HDFC Pharma and Healthcare Fund	317,568	1.66	31.18	N/A	N/A	N/A

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21
FaceValue	1.00	1.00	1.00	1.00	1.00
Basic EPS (Rs.)	52.99	4.87	-3.83	26.00	52.48
Diluted EPS (Rs.)	52.99	4.86	-3.83	26.00	52.48
Cash EPS (Rs.)	76.29	27.25	29.98	50.55	73.70
Book Value[Excl.RevalReserv]/Share (Rs.)	395.88	343.11	338.91	333.97	297.85
Book Value[Incl.RevalReserv]/Share (Rs.)	395.88	343.11	338.91	333.97	297.85
Revenue From Operations / Share (Rs.)	457.88	424.23	394.85	385.08	383.10
PBDIT / Share (Rs.)	77.88	61.36	51.20	73.35	88.83
PBIT / Share (Rs.)	54.55	37.19	16.38	49.37	66.91
PBT / Share (Rs.)	62.09	9.27	0.97	40.23	54.01
Net Profit / Share (Rs.)	52.96	3.08	-4.85	26.57	51.78
NP After MI And SOA / Share (Rs.)	53.13	4.88	-3.83	26.00	52.51
PBDIT Margin (%)	17.00	14.46	12.96	19.04	23.18
PBIT Margin (%)	11.91	8.76	4.14	12.82	17.46
PBT Margin (%)	13.56	2.18	0.24	10.44	14.09
Net Profit Margin (%)	11.56	0.72	-1.22	6.90	13.51
NP After MI And SOA Margin (%)	11.60	1.15	-0.97	6.75	13.70
Return on Networth / Equity (%)	13.41	1.41	-1.12	7.78	17.62
Return on Capital Employeed (%)	8.13	6.08	2.77	9.35	13.53
Return On Assets (%)	6.58	0.66	-0.54	4.14	9.37
Long Term Debt / Equity (X)	0.34	0.58	0.57	0.46	0.54
Total Debt / Equity (X)	0.38	0.62	0.63	0.55	0.54
Asset Turnover Ratio (%)	0.59	0.59	0.59	0.01	0.37
Current Ratio (X)	1.65	2.05	2.12	2.20	2.81
Quick Ratio (X)	1.13	1.37	1.34	1.42	1.74
Inventory Turnover Ratio (X)	5.98	1.36	1.26	0.00	1.44
Dividend Payout Ratio (NP) (%)	9.48	103.24	-130.60	19.23	0.00
Dividend Payout Ratio (CP) (%)	6.58	17.34	16.15	10.00	0.00
Earning Retention Ratio (%)	90.52	-3.24	230.60	80.77	0.00
Cash Earning Retention Ratio (%)	93.42	82.66	83.85	90.00	0.00
Interest Coverage Ratio (X)	5.12	3.56	4.33	8.03	7.68
Interest Coverage Ratio (Post Tax) (X)	2.99	1.80	0.89	3.91	4.17
Enterprise Value (Cr.)	15436.46	11426.80	6827.69	8114.60	12743.97
EV / Net Operating Revenue (X)	2.13	1.70	1.09	1.32	2.09
EV / EBITDA (X)	12.54	11.79	8.38	6.95	9.01
MarketCap / Net Operating Revenue (X)	1.95	1.34	0.70	1.01	1.78
Retention Ratios (%)	90.51	-3.24	230.60	80.76	0.00
Price / BV (X)	2.25	1.65	0.82	1.16	2.28
Price / Net Operating Revenue (X)	1.95	1.34	0.70	1.01	1.78
EarningsYield	0.05	0.01	-0.01	0.06	0.07

After reviewing the key financial ratios for Jubilant Pharmova Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
For Basic EPS (Rs.), as of Mar 25, the value is 52.99. This value is within the healthy range. It has increased from 4.87 (Mar 24) to 52.99, marking an increase of 48.12.
For Diluted EPS (Rs.), as of Mar 25, the value is 52.99. This value is within the healthy range. It has increased from 4.86 (Mar 24) to 52.99, marking an increase of 48.13.
For Cash EPS (Rs.), as of Mar 25, the value is 76.29. This value is within the healthy range. It has increased from 27.25 (Mar 24) to 76.29, marking an increase of 49.04.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 395.88. It has increased from 343.11 (Mar 24) to 395.88, marking an increase of 52.77.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 395.88. It has increased from 343.11 (Mar 24) to 395.88, marking an increase of 52.77.
For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 457.88. It has increased from 424.23 (Mar 24) to 457.88, marking an increase of 33.65.
For PBDIT / Share (Rs.), as of Mar 25, the value is 77.88. This value is within the healthy range. It has increased from 61.36 (Mar 24) to 77.88, marking an increase of 16.52.
For PBIT / Share (Rs.), as of Mar 25, the value is 54.55. This value is within the healthy range. It has increased from 37.19 (Mar 24) to 54.55, marking an increase of 17.36.
For PBT / Share (Rs.), as of Mar 25, the value is 62.09. This value is within the healthy range. It has increased from 9.27 (Mar 24) to 62.09, marking an increase of 52.82.
For Net Profit / Share (Rs.), as of Mar 25, the value is 52.96. This value is within the healthy range. It has increased from 3.08 (Mar 24) to 52.96, marking an increase of 49.88.
For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 53.13. This value is within the healthy range. It has increased from 4.88 (Mar 24) to 53.13, marking an increase of 48.25.
For PBDIT Margin (%), as of Mar 25, the value is 17.00. This value is within the healthy range. It has increased from 14.46 (Mar 24) to 17.00, marking an increase of 2.54.
For PBIT Margin (%), as of Mar 25, the value is 11.91. This value is within the healthy range. It has increased from 8.76 (Mar 24) to 11.91, marking an increase of 3.15.
For PBT Margin (%), as of Mar 25, the value is 13.56. This value is within the healthy range. It has increased from 2.18 (Mar 24) to 13.56, marking an increase of 11.38.
For Net Profit Margin (%), as of Mar 25, the value is 11.56. This value exceeds the healthy maximum of 10. It has increased from 0.72 (Mar 24) to 11.56, marking an increase of 10.84.
For NP After MI And SOA Margin (%), as of Mar 25, the value is 11.60. This value is within the healthy range. It has increased from 1.15 (Mar 24) to 11.60, marking an increase of 10.45.
For Return on Networth / Equity (%), as of Mar 25, the value is 13.41. This value is below the healthy minimum of 15. It has increased from 1.41 (Mar 24) to 13.41, marking an increase of 12.00.
For Return on Capital Employeed (%), as of Mar 25, the value is 8.13. This value is below the healthy minimum of 10. It has increased from 6.08 (Mar 24) to 8.13, marking an increase of 2.05.
For Return On Assets (%), as of Mar 25, the value is 6.58. This value is within the healthy range. It has increased from 0.66 (Mar 24) to 6.58, marking an increase of 5.92.
For Long Term Debt / Equity (X), as of Mar 25, the value is 0.34. This value is within the healthy range. It has decreased from 0.58 (Mar 24) to 0.34, marking a decrease of 0.24.
For Total Debt / Equity (X), as of Mar 25, the value is 0.38. This value is within the healthy range. It has decreased from 0.62 (Mar 24) to 0.38, marking a decrease of 0.24.
For Asset Turnover Ratio (%), as of Mar 25, the value is 0.59. There is no change compared to the previous period (Mar 24) which recorded 0.59.
For Current Ratio (X), as of Mar 25, the value is 1.65. This value is within the healthy range. It has decreased from 2.05 (Mar 24) to 1.65, marking a decrease of 0.40.
For Quick Ratio (X), as of Mar 25, the value is 1.13. This value is within the healthy range. It has decreased from 1.37 (Mar 24) to 1.13, marking a decrease of 0.24.
For Inventory Turnover Ratio (X), as of Mar 25, the value is 5.98. This value is within the healthy range. It has increased from 1.36 (Mar 24) to 5.98, marking an increase of 4.62.
For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 9.48. This value is below the healthy minimum of 20. It has decreased from 103.24 (Mar 24) to 9.48, marking a decrease of 93.76.
For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 6.58. This value is below the healthy minimum of 20. It has decreased from 17.34 (Mar 24) to 6.58, marking a decrease of 10.76.
For Earning Retention Ratio (%), as of Mar 25, the value is 90.52. This value exceeds the healthy maximum of 70. It has increased from -3.24 (Mar 24) to 90.52, marking an increase of 93.76.
For Cash Earning Retention Ratio (%), as of Mar 25, the value is 93.42. This value exceeds the healthy maximum of 70. It has increased from 82.66 (Mar 24) to 93.42, marking an increase of 10.76.
For Interest Coverage Ratio (X), as of Mar 25, the value is 5.12. This value is within the healthy range. It has increased from 3.56 (Mar 24) to 5.12, marking an increase of 1.56.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 2.99. This value is below the healthy minimum of 3. It has increased from 1.80 (Mar 24) to 2.99, marking an increase of 1.19.
For Enterprise Value (Cr.), as of Mar 25, the value is 15,436.46. It has increased from 11,426.80 (Mar 24) to 15,436.46, marking an increase of 4,009.66.
For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.13. This value is within the healthy range. It has increased from 1.70 (Mar 24) to 2.13, marking an increase of 0.43.
For EV / EBITDA (X), as of Mar 25, the value is 12.54. This value is within the healthy range. It has increased from 11.79 (Mar 24) to 12.54, marking an increase of 0.75.
For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.95. This value is within the healthy range. It has increased from 1.34 (Mar 24) to 1.95, marking an increase of 0.61.
For Retention Ratios (%), as of Mar 25, the value is 90.51. This value exceeds the healthy maximum of 70. It has increased from -3.24 (Mar 24) to 90.51, marking an increase of 93.75.
For Price / BV (X), as of Mar 25, the value is 2.25. This value is within the healthy range. It has increased from 1.65 (Mar 24) to 2.25, marking an increase of 0.60.
For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.95. This value is within the healthy range. It has increased from 1.34 (Mar 24) to 1.95, marking an increase of 0.61.
For EarningsYield, as of Mar 25, the value is 0.05. This value is below the healthy minimum of 5. It has increased from 0.01 (Mar 24) to 0.05, marking an increase of 0.04.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Jubilant Pharmova Ltd as of March 5, 2026 is: ₹935.40

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of March 5, 2026, Jubilant Pharmova Ltd is Undervalued by 10.05% compared to the current share price ₹850.00

Intrinsic Value of Jubilant Pharmova Ltd as of March 5, 2026 is: ₹943.75

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of March 5, 2026, Jubilant Pharmova Ltd is Undervalued by 11.03% compared to the current share price ₹850.00

Last 5 Year EPS CAGR: 0.89%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The company has higher reserves (4,578.23 cr) compared to borrowings (3,832.31 cr), indicating strong financial stability. The company has shown consistent growth in sales (6.08 cr) and profit (441.92 cr) over the years.	The stock has a low average ROCE of 11.08%, which may not be favorable. The stock has a high average Working Capital Days of 32.08, which may not be favorable. The stock has a high average Cash Conversion Cycle of 149.67, which may not be favorable.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Jubilant Pharmova Ltd:
1. Net Profit Margin: 11.56%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 8.13% (Industry Average ROCE: 16.35%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 13.41% (Industry Average ROE: 15.16%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 2.99
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 1.13
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 29.4 (Industry average Stock P/E: 53.22)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0.38
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Jubilant Pharmova Ltd. is a Public Limited Listed company incorporated on 21/06/1978 and has its registered office in the State of Uttar Pradesh, India. Company's Corporate Identification Number(CIN) is L24116UP1978PLC004624 and registration number is 004624. Currently Company is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company's Total Operating Revenue is Rs. 745.70 Cr. and Equity Capital is Rs. 15.90 Cr. for the Year ended 31/03/2025.

INDUSTRY	ADDRESS	CONTACT
Pharmaceuticals	Bhartiagram, Amroha District Uttar Pradesh 244223	Contact not found

Management
Name	Position Held
Mr. Shyam S Bhartia	Chairman
Mr. Hari S Bhartia	Co-Chairman
Mr. Priyavrat Bhartia	Managing Director
Mr. Arjun Shanker Bhartia	Joint Managing Director
Mr. Arvind Chokhany	WholeTime Director & Group CFO
Dr. Ramakrishnan Arul	Whole Time Director
Dr. Harsh Mahajan	Independent Director
Mr. Arun Seth	Independent Director
Mr. Vivek Mehra	Independent Director
Ms. Shivpriya Nanda	Independent Director
Mr. Shirish G Belapure	Independent Director
Mr. Sushil Kumar Roongta	Independent Director

FAQ

What is the intrinsic value of Jubilant Pharmova Ltd?

Jubilant Pharmova Ltd's intrinsic value (as of 05 March 2026) is ₹943.75 which is 11.03% higher the current market price of ₹850.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹13,546 Cr. market cap, FY2025-2026 high/low of ₹1,250/802, reserves of ₹6,576 Cr, and liabilities of ₹13,521 Cr.

What is the Market Cap of Jubilant Pharmova Ltd?

The Market Cap of Jubilant Pharmova Ltd is 13,546 Cr..

What is the current Stock Price of Jubilant Pharmova Ltd as on 05 March 2026?

The current stock price of Jubilant Pharmova Ltd as on 05 March 2026 is ₹850.

What is the High / Low of Jubilant Pharmova Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Jubilant Pharmova Ltd stocks is ₹1,250/802.

What is the Stock P/E of Jubilant Pharmova Ltd?

The Stock P/E of Jubilant Pharmova Ltd is 29.4.

What is the Book Value of Jubilant Pharmova Ltd?

The Book Value of Jubilant Pharmova Ltd is 414.

What is the Dividend Yield of Jubilant Pharmova Ltd?

The Dividend Yield of Jubilant Pharmova Ltd is 0.59 %.

What is the ROCE of Jubilant Pharmova Ltd?

The ROCE of Jubilant Pharmova Ltd is 9.54 %.

What is the ROE of Jubilant Pharmova Ltd?

The ROE of Jubilant Pharmova Ltd is 9.55 %.

What is the Face Value of Jubilant Pharmova Ltd?

The Face Value of Jubilant Pharmova Ltd is 1.00.